Addex Therapeutics Ltd. filings document a foreign private issuer and ADR-linked clinical-stage biotechnology company focused on small-molecule allosteric modulators. Form 6-K reports furnish press releases, financial results, interim condensed consolidated financial statements, MD&A, iXBRL exhibits, and risk-factor updates incorporated into Form F-3 and Form S-8 registration statements.
The disclosures cover pipeline programs such as GABAB PAM candidates, mGlu receptor modulators, ADX71149, and Neurosterix-related NTX-253, along with collaboration and licensing arrangements, strategic investments, cash resources, governance, equity-plan registrations, and foreign-issuer reporting under Form 20-F.
Addex Therapeutics Ltd files its annual report on Form 20-F, highlighting a development-stage biotech business with ongoing losses and tight liquidity. The company incurred an accumulated loss of CHF 360 million since inception and reported a net loss of CHF 6.7 million for the year ended December 31, 2025, compared to a net profit of CHF 7.1 million a year earlier, when results benefited from a business sale.
As of December 31, 2025, Addex held cash and cash equivalents of CHF 1.6 million and expects this to fund operations only through mid‑June 2026, so it will need significant additional capital from partnerships, IP monetization and equity offerings. The company sold its allosteric modulator discovery platform and certain preclinical programs to Neurosterix in April 2024 for CHF 5.0 million and a 20% equity stake, and now relies heavily on partners such as Indivior and Neurosterix for development, infrastructure and potential milestone revenue. The filing details extensive risks around financing, regulatory approvals, reliance on third parties, intellectual property, data protection, healthcare policy changes and potential Nasdaq delisting pressure.
Addex Therapeutics reported full-year 2025 results with a net loss of CHF 6.7 million, compared with a profit of CHF 7.1 million in 2024, and cash and cash equivalents of CHF 1.6 million at December 31, 2025. Income from continuing operations fell to CHF 0.2 million as the research phase of the Indivior collaboration ended mid-2024. R&D expenses declined to CHF 0.7 million, while G&A remained stable at CHF 2.3 million. Losses from associates increased to CHF 4.0 million due to its 20% stake in Neurosterix US Holdings LLC. Shareholders’ equity decreased to CHF 4.8 million.
Operationally, Addex advanced its GABAB PAM program for chronic cough, progressed dipraglurant (an mGlu5 NAM) toward clinical studies in brain injury recovery, and regained rights to the Phase 2 mGlu2 PAM asset ADX71149. It also entered an option and collaboration agreement with Sinntaxis on mGlu5 NAM for brain injury and maintained a strategic investment portfolio, including Neurosterix and Stalicla. The company scheduled a conference call on April 30, 2026, to discuss these results and its pipeline progress.
Addex Therapeutics filed a Form 6-K to furnish a press release highlighting new preclinical results for its GABAB positive allosteric modulator (PAM) candidate in an idiopathic pulmonary fibrosis (IPF)-related chronic cough model. In bleomycin-exposed animals, once-daily dosing produced robust and sustained reductions in cough frequency and longer cough latency, along with improved lung pathology measures such as lower Ashcroft scores and less affected lung tissue. The compound showed a favorable safety profile with stable respiratory rate and body temperature and was well tolerated, supporting its potential for chronic use in chronic cough. The company also reiterates broader work on allosteric modulators in neurological and related disorders.
Addex Therapeutics reported that its spin-out company Neurosterix remains on track to complete a Phase 1 clinical study of NTX-253 for schizophrenia in Q2 2026. NTX-253 is an oral, potent, selective positive allosteric modulator of the muscarinic M4 receptor, aiming to treat schizophrenia by indirectly modulating dopamine signaling.
The Phase 1 program includes single ascending dose and multiple ascending dose components in healthy adults and adults with stable schizophrenia, assessing safety, tolerability, pharmacokinetics, food effects and cerebrospinal fluid exposure. Neurosterix, spun out of Addex in April 2024, raised $65 million in Series A financing, and Addex retains a 20% equity interest in the company.
Addex Therapeutics reported new preclinical data showing its novel GABAB positive allosteric modulator (PAM) produced robust anti-tussive, or cough-suppressing, activity in a non-human primate chronic cough model. The candidate significantly reduced citric acid-induced cough frequency with efficacy similar to baclofen.
Previously reported guinea pig data showed the same GABAB PAM reduced cough frequency, increased cough latency and did not show tolerance after sub-chronic treatment, with antitussive effects appearing superior to nalbuphine, baclofen, codeine and a P2X3 inhibitor. The compound also demonstrated better tolerability and a wider therapeutic margin than nalbuphine, baclofen or codeine, and similar tolerability to a P2X3 inhibitor based on respiratory rate.
Addex is advancing this GABAB PAM program for chronic cough alongside other allosteric modulator programs, including its lead candidate dipraglurant for brain injury recovery and partnered GABAB PAM development in substance use disorders.
Addex Therapeutics Ltd. director and chief medical officer Roger Mills reported his initial holdings. He directly owns 785,976 shares of Common Stock listed on the SIX Swiss Exchange and holds stock options over 50,000 shares, exercisable at $0.0640 per share.
The options began vesting in equal monthly installments over four years from the exercisable date of January 8, 2024 and expire on January 7, 2034. The exercise price is shown in U.S. dollars using an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.
Addex Therapeutics Ltd. director Vincent Michael Lawton has filed a Form 3 reporting his initial beneficial ownership in the company. He holds 2,507,987 shares of Common Stock listed on the SIX Swiss Exchange and a stock option award over 501,598 shares of Common Stock.
The stock options carry an exercise price of $0.064 per share, based on a CHF-to-USD exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026. These options began vesting in equal monthly installments over a four-year period starting January 8, 2024 and expire on January 7, 2034.
Addex Therapeutics Ltd. principal accounting officer Lenaic Nathanael Teyssedou filed an initial ownership report showing multiple stock-option awards over Addex common shares. These options are rights to buy shares at fixed prices and represent existing compensation grants, not new share purchases or sales.
The filing lists several option grants with exercise prices of $0.1660, $0.0550, and $0.0640 per share, expiring between 2027 and 2034. According to the footnotes, each option gives the right to buy one ADXN share, vesting in equal monthly installments over four years, and the exercise prices are reported in U.S. dollars using a $1.2769 per CHF $1.00 exchange rate as of March 12, 2026.
Addex Therapeutics Ltd. executive Mikhail Kalinichev filed an initial ownership report showing his equity stake in the company. He directly holds 306,765 shares of Common Stock listed on SIX Swiss Exchange and a stock option covering 200,000 shares at an exercise price of $0.0640 per share. The option is exercisable from August 1, 2024, vests in equal monthly installments over four years, and expires on January 7, 2034. Each option entitles him to purchase one ADXN share on SIX Swiss Exchange.
Addex Therapeutics Ltd. director Raymond George Hill filed an initial ownership report showing his equity position in the company. He holds 1,365,532 shares of Common Stock listed on the SIX Swiss Exchange and a stock option over 273,107 shares of Common Stock.
The stock option has an exercise price of $0.0640 per share, becomes exercisable in equal monthly installments over a four-year period beginning on the exercisable date, and expires on January 7, 2034. The exercise price reflects conversion from Swiss francs at an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.